β-lapachone, a major component in an ethanol extract of Tabebuia avellanedae bark, is a promising potential therapeutic drug for various tumors, including lung cancer, the leading cause of cancer-related deaths worldwide. In the first part of this study, we found that apoptotic cell death induced in lung cancer cells by high concentrations of β-lapachone was mediated by increased activation of the pro-apoptotic factor JNK and decreased activation of the cell survival/proliferation factors PI3K, AKT, and ERK. In addition, β-lapachone toxicity was positively correlated with the expression and activity of NAD(P)H quinone oxidoreductase 1 (NQO1) in the tumor cells. In the second part, we found that the FDA-approved non-steroidal anti-inflammatory drug sulindac and its metabolites, sulindac sulfide and sulindac sulfone, increased NQO1 expression and activity in the lung adenocarcinoma cell lines CL1-1 and CL1-5, which have lower NQO1 levels and lower sensitivity to β-lapachone treatment than the A549 cell lines, and that inhibition of NQO1 by either dicoumarol treatment or NQO1 siRNA knockdown inhibited this sulindac-induced increase in β-lapachone cytotoxicity. In conclusion, sulindac and its metabolites synergistically increase the anticancer effects of β-lapachone primarily by increasing NQO1 activity and expression, and these two drugs may provide a novel combination therapy for lung cancers.
References
[1]
Pardee AB, Li YZ, Li CJ (2002) Cancer therapy with beta-lapachone. Curr Cancer Drug Targets 2: 227–242. doi: 10.2174/1568009023333854
[2]
Tagliarino C, Pink JJ, Reinicke KE, Simmers SM, Wuerzberger-Davis SM, et al. (2003) Mu-calpain activation in beta-lapachone-mediated apoptosis. Cancer Biol Ther 2: 141–152. doi: 10.4161/cbt.2.2.237
[3]
Tan XL, Marquardt G, Massimi AB, Shi M, Han W, et al. (2012) High-throughput library screening identifies two novel NQO1 inducers in human lung cells. Am J Respir Cell Mol Biol 46: 365–371. doi: 10.1165/rcmb.2011-0301oc
[4]
Minami T, Adachi M, Kawamura R, Zhang Y, Shinomura Y, et al. (2005) Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity. Clin Cancer Res 11: 5248–5256. doi: 10.1158/1078-0432.ccr-05-0085
[5]
Terai K, Dong GZ, Oh ET, Park MT, Gu Y, et al. (2009) Cisplatin enhances the anticancer effect of beta-lapachone by upregulating NQO1. Anticancer Drugs 20: 901–909. doi: 10.1097/cad.0b013e328330098d
[6]
Tagliarino C, Pink JJ, Dubyak GR, Nieminen AL, Boothman DA (2001) Calcium is a key signaling molecule in beta-lapachone-mediated cell death. J Biol Chem 276: 19150–19159. doi: 10.1074/jbc.m100730200
[7]
Bentle MS, Reinicke KE, Dong Y, Bey EA, Boothman DA (2007) Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone. Cancer Res 67: 6936–6945. doi: 10.1158/0008-5472.can-07-0935
[8]
Planchon SM, Pink JJ, Tagliarino C, Bornmann WG, Varnes ME, et al. (2001) beta-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3. Exp Cell Res 267: 95–106. doi: 10.1006/excr.2001.5234
[9]
Reinicke KE, Bey EA, Bentle MS, Pink JJ, Ingalls ST, et al. (2005) Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels. Clin Cancer Res 11: 3055–3064. doi: 10.1158/1078-0432.ccr-04-2185
[10]
de Witte NV, Stoppani AO, Dubin M (2004) 2-Phenyl-beta-lapachone can affect mitochondrial function by redox cycling mediated oxidation. Arch Biochem Biophys 432: 129–135. doi: 10.1016/j.abb.2004.09.020
[11]
Pink JJ, Wuerzberger-Davis S, Tagliarino C, Planchon SM, Yang X, et al. (2000) Activation of a cysteine protease in MCF-7 and T47D breast cancer cells during beta-lapachone-mediated apoptosis. Exp Cell Res 255: 144–155. doi: 10.1006/excr.1999.4790
[12]
Choi EK, Terai K, Ji IM, Kook YH, Park KH, et al. (2007) Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells. Neoplasia 9: 634–642. doi: 10.1593/neo.07397
[13]
Lemasters JJ, Nieminen AL, Qian T, Trost LC, Elmore SP, et al. (1998) The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1366: 177–196. doi: 10.1016/s0005-2728(98)00112-1
[14]
Smaili SS, Hsu YT, Youle RJ, Russell JT (2000) Mitochondria in Ca2+ signaling and apoptosis. J Bioenerg Biomembr 32: 35–46.
[15]
Belinsky M, Jaiswal AK (1993) NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev 12: 103–117. doi: 10.1007/bf00689804
[16]
Satsu H, Chidachi E, Hiura Y, Ogiwara H, Gondo Y, et al.. (2012) Induction of NAD(P)H:quinone oxidoreductase 1 expression by cysteine via Nrf2 activation in human intestinal epithelial LS180 cells. Amino Acids.
[17]
Tsai CW, Lin CY, Wang YJ (2011) Carnosic acid induces the NAD(P)H: quinone oxidoreductase 1 expression in rat clone 9 cells through the p38/nuclear factor erythroid-2 related factor 2 pathway. J Nutr 141: 2119–2125. doi: 10.3945/jn.111.146779
[18]
Bottone FG Jr, Martinez JM, Collins JB, Afshari CA, Eling TE (2003) Gene modulation by the cyclooxygenase inhibitor, sulindac sulfide, in human colorectal carcinoma cells: possible link to apoptosis. J Biol Chem 278: 25790–25801. doi: 10.1074/jbc.m301002200
[19]
Dong GZ, Youn H, Park MT, Oh ET, Park KH, et al. (2009) Heat shock increases expression of NAD(P)H:quinone oxidoreductase (NQO1), mediator of beta-lapachone cytotoxicity, by increasing NQO1 gene activity and via Hsp70-mediated stabilisation of NQO1 protein. Int J Hyperthermia 25: 477–487. doi: 10.1080/02656730903049836
[20]
Tugwell P, Ludwin D, Gent M, Roberts R, Bensen W, et al. (1997) Interaction between cyclosporin A and nonsteroidal antiinflammatory drugs. J Rheumatol 24: 1122–1125.
[21]
Muncie HL, Jr. (1986) Medical aspects of the multidisciplinary assessment and management of osteoarthritis. Clin Ther 9 Suppl B: 4–13.
[22]
Fernandes E, Toste SA, Lima JL, Reis S (2003) The metabolism of sulindac enhances its scavenging activity against reactive oxygen and nitrogen species. Free Radic Biol Med 35: 1008–1017. doi: 10.1016/s0891-5849(03)00437-4
[23]
Karachalios GN, Donas G (1982) Sulindac in the treatment of acute gout arthritis. Int J Tissue React 4: 297–299.
[24]
Klassen DK, Stout RL, Spilman PS, Whelton A (1989) Sulindac kinetics and effects on renal function and prostaglandin excretion in renal insufficiency. J Clin Pharmacol 29: 1037–1042. doi: 10.1002/j.1552-4604.1989.tb03275.x
[25]
Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94: 252–266. doi: 10.1093/jnci/94.4.252
[26]
Ruegg C, Zaric J, Stupp R (2003) Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and reality. Ann Med 35: 476–487. doi: 10.1080/07853890310017053
[27]
Hisamuddin IM, Wehbi MA, Chao A, Wyre HW, Hylind LM, et al. (2004) Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis. Clin Cancer Res 10: 8357–8362. doi: 10.1158/1078-0432.ccr-04-1073
[28]
Ciolino HP, Bass SE, MacDonald CJ, Cheng RY, Yeh GC (2008) Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. Int J Cancer 122: 990–998. doi: 10.1002/ijc.23218
[29]
Resnick L, Rabinovitz H, Binninger D, Marchetti M, Weissbach H (2009) Topical sulindac combined with hydrogen peroxide in the treatment of actinic keratoses. J Drugs Dermatol 8: 29–32.
[30]
Marchetti M, Resnick L, Gamliel E, Kesaraju S, Weissbach H, et al. (2009) Sulindac enhances the killing of cancer cells exposed to oxidative stress. PLoS One 4: e5804. doi: 10.1371/journal.pone.0005804
[31]
van Lieshout EM, Tiemessen DM, Peters WH, Jansen JB (1997) Effects of nonsteroidal anti-inflammatory drugs on glutathione S-transferases of the rat digestive tract. Carcinogenesis 18: 485–490. doi: 10.1093/carcin/18.3.485
[32]
Patten EJ, DeLong MJ (1999) Effects of sulindac, sulindac metabolites, and aspirin on the activity of detoxification enzymes in HT-29 human colon adenocarcinoma cells. Cancer Lett 147: 95–100. doi: 10.1016/s0304-3835(99)00282-7
[33]
Oberg M, Jaakkola MS, Woodward A, Peruga A, Pruss-Ustun A (2011) Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries. Lancet 377: 139–146. doi: 10.1016/s0140-6736(10)61388-8
[34]
Gan Q, Smith KR, Hammond SK, Hu TW (2007) Disease burden of adult lung cancer and ischaemic heart disease from passive tobacco smoking in China. Tob Control 16: 417–422. doi: 10.1136/tc.2007.021477
[35]
Thill PG, Goswami P, Berchem G, Domon B (2011) Lung cancer statistics in Luxembourg from 1981 to 2008. Bull Soc Sci Med Grand Duche Luxemb: 43–55.
[36]
Earle CC (2004) Outcomes research in lung cancer. J Natl Cancer Inst Monogr: 56–77.
[37]
Dienstmann R, Brana I, Rodon J, Tabernero J (2011) Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist 16: 1729–1740. doi: 10.1634/theoncologist.2011-0163
[38]
Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, et al. (2011) Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther 10: 336–346. doi: 10.1158/1535-7163.mct-10-0750
[39]
Gupta AK, Soto DE, Feldman MD, Goldsmith JD, Mick R, et al. (2004) Signaling pathways in NSCLC as a predictor of outcome and response to therapy. Lung 182: 151–162. doi: 10.1007/s00408-004-0310-8
[40]
Naime FF, Younes RN, Kersten BG, Anelli A, Beato CA, et al. (2007) Metastatic non-small cell lung cancer in Brazil: treatment heterogeneity in routine clinical practice. Clinics (Sao Paulo) 62: 397–404.
[41]
Spivack SD, Hurteau GJ, Fasco MJ, Kaminsky LS (2003) Phase I and II carcinogen metabolism gene expression in human lung tissue and tumors. Clin Cancer Res 9: 6002–6011.
[42]
Kolesar JM, Pritchard SC, Kerr KM, Kim K, Nicolson MC, et al. (2002) Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. Int J Oncol 21: 1119–1124. doi: 10.3892/ijo.21.5.1119
[43]
Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix MJ, et al. (1997) Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 17: 353–360. doi: 10.1165/ajrcmb.17.3.2837
[44]
Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, et al. (2000) NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J Biol Chem 275: 5416–5424. doi: 10.1074/jbc.275.8.5416
[45]
Lien YC, Kung HN, Lu KS, Jeng CJ, Chau YP (2008) Involvement of endoplasmic reticulum stress and activation of MAP kinases in beta-lapachone-induced human prostate cancer cell apoptosis. Histol Histopathol 23: 1299–1308.
[46]
Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, et al. (2011) Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 3: 192–222.
[47]
Kutuk O, Basaga H (2007) Apoptosis signalling by 4-hydroxynonenal: a role for JNK-c-Jun/AP-1 pathway. Redox Rep 12: 30–34. doi: 10.1179/135100007x162329
[48]
Saeki K, Kobayashi N, Inazawa Y, Zhang H, Nishitoh H, et al. (2002) Oxidation-triggered c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein (MAP) kinase pathways for apoptosis in human leukaemic cells stimulated by epigallocatechin-3-gallate (EGCG): a distinct pathway from those of chemically induced and receptor-mediated apoptosis. Biochem J 368: 705–720. doi: 10.1042/bj20020101
[49]
Lee H, Park MT, Choi BH, Oh ET, Song MJ, et al. (2011) Endoplasmic reticulum stress-induced JNK activation is a critical event leading to mitochondria-mediated cell death caused by beta-lapachone treatment. PLoS One 6: e21533. doi: 10.1371/journal.pone.0021533
[50]
Orrenius S, Zhivotovsky B, Nicotera P (2003) Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol 4: 552–565. doi: 10.1038/nrm1150
[51]
Cresteil T, Jaiswal AK (1991) High levels of expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin. Biochem Pharmacol 42: 1021–1027. doi: 10.1016/0006-2952(91)90284-c
[52]
Schlager JJ, Powis G (1990) Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer 45: 403–409. doi: 10.1002/ijc.2910450304
[53]
Smitskamp-Wilms E, Giaccone G, Pinedo HM, van der Laan BF, Peters GJ (1995) DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? Br J Cancer 72: 917–921.
[54]
Marin A, Lopez de Cerain A, Hamilton E, Lewis AD, Martinez-Penuela JM, et al. (1997) DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours. Br J Cancer 76: 923–929.
[55]
Berger MS, Talcott RE, Rosenblum ML, Silva M, AliOsman F, et al. (1985) Use of quinones in brain-tumor therapy: preliminary results of preclinical laboratory investigations. J Toxicol Environ Health 16: 713–719. doi: 10.1080/15287398509530781
[56]
Park EJ, Choi KS, Kwon TK (2011) beta-Lapachone-induced reactive oxygen species (ROS) generation mediates autophagic cell death in glioma U87 MG cells. Chem Biol Interact 189: 37–44. doi: 10.1016/j.cbi.2010.10.013
[57]
Suzuki M, Amano M, Choi J, Park HJ, Williams BW, et al. (2006) Synergistic effects of radiation and beta-lapachone in DU-145 human prostate cancer cells in vitro. Radiat Res 165: 525–531. doi: 10.1667/rr3554.1
[58]
Vane JR, Flower RJ, Botting RM (1990) History of aspirin and its mechanism of action. Stroke 21: IV12–23.
[59]
Horton JK, Williams AS, Smith-Phillips Z, Martin RC, O’Beirne G (1999) Intracellular measurement of prostaglandin E2: effect of anti-inflammatory drugs on cyclooxygenase activity and prostanoid expression. Anal Biochem 271: 18–28. doi: 10.1006/abio.1999.4118
[60]
Waddell WR, Loughry RW (1983) Sulindac for polyposis of the colon. J Surg Oncol 24: 83–87. doi: 10.1002/jso.2930240119
[61]
PDQ Clinical Trail Database, National Cancer Institure.
[62]
Ciolino HP, MacDonald CJ, Memon OS, Bass SE, Yeh GC (2006) Sulindac regulates the aryl hydrocarbon receptor-mediated expression of Phase 1 metabolic enzymes in vivo and in vitro. Carcinogenesis 27: 1586–1592. doi: 10.1093/carcin/bgi359
[63]
Lin X, Yang H, Zhou L, Guo Z (2011) Nrf2-dependent induction of NQO1 in mouse aortic endothelial cells overexpressing catalase. Free Radic Biol Med 51: 97–106. doi: 10.1016/j.freeradbiomed.2011.04.020
[64]
Yamamoto Y, Yin MJ, Lin KM, Gaynor RB (1999) Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 274: 27307–27314. doi: 10.1074/jbc.274.38.27307
[65]
Zhang T, Fields JZ, Ehrlich SM, Boman BM (2004) The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells. J Pharmacol Exp Ther 308: 434–437. doi: 10.1124/jpet.103.059378
[66]
Hebbar V, Shen G, Hu R, Kim BR, Chen C, et al. (2005) Toxicogenomics of resveratrol in rat liver. Life Sci 76: 2299–2314. doi: 10.1016/j.lfs.2004.10.039
[67]
Gustafson DL, Beall HD, Bolton EM, Ross D, Waldren CA (1996) Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones. Mol Pharmacol 50: 728–735.
[68]
Cross JV, Deak JC, Rich EA, Qian Y, Lewis M, et al. (1999) Quinone reductase inhibitors block SAPK/JNK and NFkappaB pathways and potentiate apoptosis. J Biol Chem 274: 31150–31154. doi: 10.1074/jbc.274.44.31150
